Research programme: anti-ceramide antibodies - Ceramedix
Latest Information Update: 31 Aug 2023
At a glance
- Originator Ceramedix
- Class Immunoglobulin Fv fragments; Monoclonal antibodies; Radioprotectives; Recombinant fusion proteins
- Mechanism of Action Cell death inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute radiation syndrome
Most Recent Events
- 29 Aug 2023 Ceramedix has patent protection for anti-ceramide antibodies in multiple countries (WO 201 602 288 3A1)
- 24 Aug 2023 Ceramedix receives Phase 2B NIH SBIR grant from NIAID for anti-ceramide antibody development in Acute radiation syndrome
- 24 Aug 2023 Preclinical trials in Acute radiation syndrome in USA (SC)